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Abstract
Background: Tumour excision with negative margins is the
ultimate goal following soft tissue sarcoma excision, but
obtaining this goal can come at a cost with high wound
complication rates reported. There is however an emerging
body of evidence that primary application of a negative
pressure dressing can significantly decrease the risk of
developing post-operative wound complications. This paper
describes the study protocol for an interventional
randomized controlled trial, comparing the efficacy of
negative pressure dressings against standard dressings on
primary closed wounds following soft tissue sarcoma
excision.
Questions/Purposes: Does primary application of negative
pressure dressing to closed wounds post soft tissue sarcoma
excision reduce wound complications when compared to
standard dressings?
Level of evidence: Level I, Prospective RCT
Keywords: Sarcoma; Negative pressure dressing; Control
trial; Wound management
Introduction
Background
Soft tissue sarcomas are rare tumours of mesenchymal cell
origin representing under 1% of all adult tumours in the United
Kingdom [1]. Principles of treatment have evolved over the last
decade from primary amputation to limb preservation, with
tumour resection and negative margins the ultimate goal [2].
Ensuring clear margins, however, can come at a cost. Large
wounds with a disrupted vascular supply and lymphatic drainage
may result in increased wound complications such as infection,
dehiscence and delayed wound healing [3,4]. Wound problems
remain one of the most common complications following
resection of a soft tissue sarcoma and represent a major source
of post-operative morbidity. Peat et al. report wound
complication rates of 16% [4], however Baldini et al. suggest
rates as high as 56%, especially seen in those who have
undergone neo-adjuvant radiotherapy or with margins close to
the skin surface [5]. In the last 15 years there is an emerging
body of evidence suggesting a reduction in wound complications
with the primary application of a negative pressure dressing
[6,7,8,9-11]. However, the negative pressure dressings typically
have an increased cost and added complexity in usage compared
to conventional dressings, meaning that their routine use
remains elusive. Within the high-risk group of patients
undergoing resection of a soft tissue sarcoma there is little
evidence of the beneficial use of negative pressure dressings. A
recent case-controlled study performed at our unit, however,
demonstrates encouraging results with zero surgical site
complications in patients who underwent sarcoma resection
followed by primary wound closure and application of a negative
pressure dressing [8].
Rationale
The aim of this trial is to compare the effectiveness of
negative pressure dressing on closed wounds following soft
tissue sarcoma excision. Our null hypothesis is there will be no
difference in surgical site infections (as defined by the Health
Protection Agency) between wounds covered by negative
pressure dressings and those covered in standard dressings
following soft tissue sarcoma excision.
Study question
Does primary application of negative pressure dressing to
closed wounds post soft tissue sarcoma excision reduce wound
complications when compared to standard dressings?
Methods
Study design and setting
This is an interventional prospective randomized control trial,
comparing the efficacy of negative pressure dressings against
standard dressings on primary closed wounds following soft
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tissue sarcoma excision. Patients will be initially recruited from
the West of Scotland Regional Sarcoma Service based at
Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde. Our
aim however is to expand recruitment to other specialist
centers.
Participants/study subjects
Patients will be identified by Orthopedic Musculoskeletal
(MSK) Oncology specialists at the time of diagnosis and when
the decision for operative intervention has been planned.
Eligibility for inclusion will be made by the principle investigator,
or a suitably qualified delegated MSK specialist.
Inclusion criteria
• Diagnosis of soft tissue sarcoma on the upper limb, lower
limb, or torso
• Consented for wide local excision or planned marginal
excision of the tumour
• Age 16-85 years inclusive
• English speaking
Exclusion criteria
• Previous surgery to planned surgical field
• Contra-indication to surgical excision of the tumour
• Primary preferred management via amputation
• Disseminated malignancy on pre-operative radiological
imaging
• Post-radiation sarcoma
• Allergy to adhesive dressing
• Current psychological condition that will affect compliance to
follow up
• Patients refusal for inclusion
Consent procedures
Patients are fully informed and consent obtained prior to
inclusion in this study. All patients will be provided with a
patient information sheet and have the opportunity to discuss
the trial with both an impartial expert and the principle
investigator at their first orthopaedic appointment. The patient
will be given at least 24 h to review the information sheet and
digest information given to them prior to obtaining full written
informed consent at a subsequent clinic appointment prior to
surgery. All patients will be provided with a direct phone
number to an oncology nurse specialist who is highly
experienced in sarcoma medical and surgical management, but
also independent from the study data collection and analysis.
The process of consent will be in accordance with the
Declaration of Helsinki (2013).
Description of experiment and treatment
Study Group 1: Standard dressing. The soft tissue sarcoma will
be excised as a wide local excision or planned marginal excision
as per the pre-operative plan. The wound will be closed in layers
as per standard surgical technique with skin closure as per the
operating surgeon’s preference with the absence of skin glue.
Wounds will be covered in a conventional absorbent transparent
dressing. Low-molecular weight heparin thromboprophylaxis will
be provided to all patients post-operatively until discharge as
per local protocol.
Study Group 2: Negative pressure dressing. The soft tissue
sarcoma will be excised as a wide local excision or planned
marginal excision as per the pre-operative plan. The wound will
be closed in layers as per standard surgical technique with skin
closure as per the operating surgeon’s preference with the
absence of skin glue. A mesh based dressing will be applied to
the wound following by a transparent occlusive dressing as per
the manufacturer’s instruction. The dressing will then be
connected to a suction device (ActiV.A.C.®, KCI), providing a
constant negative pressure of 120 mmHg. The negative pressure
dressing will be left in-situ for 5-6 days as per the manufactures
instructions. Low-molecular weight heparin thromboprophylaxis
will be provided to all patients post-operatively until discharge
as per local protocol.
Aftercare
All patients will have the same standardized post-operative
wound management including intravenous antibiotics until
surgical drains are removed. Dressings will be clinically assessed
daily until discharge by the operating team or by a designated
specialist nurse as appropriate.
Description of followup routine
Outpatient follow-up will be pragmatic depending on post-
operative wound healing with standardized follow-up planned
for all patients at 30 days post-operatively. An adverse event will
be defined as any untoward medical occurrence that the patient
experiences whilst participating in the study. These will be
immediately reported to the Principle Investigator and recorded
in the patient’s records as per standard policy.
Variables and outcome measures
Primary Outcome:
Any surgical site infection (SSI) as defined by the Health
Protection Agency by day 30 post-operatively [12].
Secondary Outcomes:
• Wound dehiscence or further surgery to the operative site by
day 30 post-operatively
• Time to wound dryness-day post-operative where there has
been 12 h with no further wetness on the dressing or no
further volume in VAC unit (days)
• Surgical drain duration and volume (ml)
• Duration of hospital inpatient stay (days)
• Functional assessments
1. TESS (Toronto Extremity Salvage Score) [13].
2. MSTS (Musculoskeletal Tumour Society) score at 3, 6, and
12 months post-operatively [14].
• Adverse events-Any unanticipated events (morbidity,
mortality, reaction of dressing)
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Data collection
Baseline data will be collected from both paper notes and
electronic patient databases (Bluespeir, Worcestershire, UK).
Data will be anonymised and collated on Excel (Microsoft©,
USA) by a blinded researcher. Baseline data will include: Age,
gender, weight, height, ASA grade, smoking status, significant
medical history, diagnosis [15], any intra-operative complication,
drain volume, length of surgery, length of hospital stay, grade of
operating surgeon, and any adjuvant chemotherapy or
radiotherapy within the 30-day post-operative period.
Primary outcome of surgical site infection and secondary
outcomes of wound dehiscence or further surgery will be
recorded at any time point of inpatient or outpatient follow-up
up to 30 days post-operatively. Time to wound dryness, as
defined by no new staining on the wound dressing in a 12 h
period, will be made by a specialist oncology nurse during the
patients inpatient stay. Functional assessments will be made
pre-operatively and post-operatively at 3, 6, and 12 months
post-operatively.
Ethical approval
Ethical approval has been obtained via the West of Scotland
Research Ethical Committee-(approval number 16/WS/0146) as
part of the national Integrated Research Application System.
Statistical analysis, study size
We have estimated current SSI rate to be 20% following
excision of a soft tissue sarcoma and standard wound dressing
based on the literature [4] and our internal outcome data. A
case-control trial performed at our unit demonstrated zero SSI’s
after negative dressing application in a cohort of 9 patients who
underwent sarcoma excision [8]. We propose a clinically
significant improvement in SSI rate to be 15%, thereby aiming
for an overall SSI rate of 5%. Power calculation for the primary
outcome with a 95% confidence interval and power set to 0.80
the sample size was calculated at 77 patients per arm. Allowing
for 10% loss to follow-up, we aim to recruit 85 patients per arm.
If a patient declines or was unable to continue in their assigned
group they will be analysed in their assigned group as per the
intention to treat concept.
Results
Publication and dissemination of findings to medical
practitioners, patients, and key stakeholders will be undertaken
through a number of methods:
• The study protocol and findings will be submitted for
publication in peer-reviewed journals
• Findings will be presented at national and international
meetings. These will include both general orthopedic and
specialist musculoskeletal oncology conferences.
Discussion
This paper describes the study protocol 2.7 (14th Sept 2016)
for the SUNstudy, which has been fully approved by ethics. Our
intention is for expansion to multicentres with recruitment
starting at our site in the near future.
Randomized Controlled Trial (RCT) Details
Registry Name: www.clinicaltrials.gov
Registration Number: NCT02901405
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